Clinical Development Programs

The Astellas partnership includes a treatment for hypercholesterolemia (evolocumab), a treatment for osteoporosis (romosozumab) and a treatment for oncology (blinatumomab).

Co-developed Pipeline Medicines between Amgen Astellas BioPharma and Astellas Pharma

General Name
(Development Code)
Lead Indication Mode of Action Development Stage
Overseas Japan
Evolocumab (AMG 145) Hypercholesterolemia Anti-PCSK-9 mAb Launch Launch
Romosozumab (AMG 785)1 Osteoporosis Anti-Sclerostin mAb Phase 3 Phase 3
Blinatumomab (AMG 103) Acute Lymphoblastic
Leukemia (ALL)
Anti-CD19 BiTE® Launch Phase 2

As of July, 2016

1  Developed in collaboration with UCB

Pipeline Medicines by Amgen Astellas BioPharma

General Name
(Development Code)
Lead Indication Mode of Action Development Stage
Overseas Japan
AMG 678 Malignant Melanoma Oncolytic Virus Launch Phase 1
AMG 334 Migraine prevention Anti-CGRP Receptor
mAb
Phase 3 Phase 2
AMG 423 Chronic heart failure Cardiac myosin
activator
Phase 2 Phase 2

As of July, 2016